Objective To investigate the risk of decreased estimated glomerular filtration rate (eGFR) and proteinuria among individuals with borderline diabetes. Methods This 5-year cohort study involved 2849 participants aged 30-79 years without diabetes or chronic kidney disease at baseline (April 2008-March 2009 
Introduction
The number of patients with end-stage renal disease (ESRD) is increasing worldwide [1] . Dialysis associated with ESRD lowers patient quality of life and increases national medical care expenditure. Additionally, ESRD is a major risk factor for cardiovascular disease. Diabetes is the primary cause of ESRD in Japan [2] , and patients with ESRD and diabetes are at particularly high risk for cardiovascular disease [3] . Therefore, preventing ESRD among patients with diabetes is important.
Although chronic kidney disease (CKD) generally occurs 10 or 15 years after diabetes onset [4] , the duration of diabetes without subjective symptoms is often difficult to determine. Recently, it has been reported that impaired glucose tolerance is associated with the development of retinopathy, a microvascular complication of diabetes [5] . It is likely that early-stage CKD, another microvascular complication, also begins at the borderline diabetes stage. To prevent ESRD among patients with diabetes, early detection of and intervention for early-stage CKD are important.
Because borderline diabetes fluctuates between the development of diabetes and reverting back to normoglycemia, it is difficult to determine whether borderline diabetes is a risk factor for CKD. In a prospective study of a Japanese population, we investigated whether individuals with borderline diabetes develop proteinuria or experience a decreased estimated glomerular filtration rate (eGFR), which are indices of CKD. Changes in the diabetes stage of each study participant during the follow-up period were considered in order to estimate the risk of participants with borderline diabetes developing CKD.
Methods Participants
The details of this study have been described previously [6, 7] . The cohort included 4910 individuals aged 30-79 years who underwent a baseline comprehensive medical checkup over 2 days and 1 night between April 2008 and March 2009 at Saku Central Hospital. Of these individuals, 2061 were excluded for the following reasons: past or present history of ESRD, eGFR \60 ml/min/1.73 m 2 , proteinuria C[1?], past or present history of diabetes, fasting plasma glucose (FPG) level C126 mg/dl, 2-h plasma glucose (PG) level C200 mg/dl, or missing data. The remaining 2849 participants were included in the analysis. The study protocol was in accordance with the Declaration of Helsinki, and was approved by the Ethics Committee of Saku Central Hospital. An opt-out consent procedure was implemented. The standard questionnaires included opt-out information.
Data collection
During the morning after an overnight fast (10 h), all participants underwent a standard 75-g oral glucose tolerance test (OGTT). Blood samples were obtained at 0 (fasting), 30, 60, and 120 min. Diabetes stage was determined by FPG and 2-h PG according to the Japan Diabetes Society criteria [8] . Participants were classified into two groups: normoglycemia (FPG \ 110 mg/dl and 2-h PG \ 140 mg/dl) and borderline diabetes (FPG \ 126 mg/dl and 2-h PG \ 200 mg/dl but not normoglycemia). Blood glucose was measured by an electrode method. Total cholesterol, serum creatinine, and serum triglyceride concentrations were measured by enzymatic methods. eGFR was calculated by the following formula: 194 9 Cr -1.094 9 age -0.287
for men, 194 9 Cr -1.094 9 age -0.287 9 0.739 for women [9] . High-sensitivity C-reactive protein (hsCRP) concentrations were measured using the latex immunity turbidimetric method, and HbA 1c concentrations were measured by high-performance liquid chromatography. HbA 1c (%) was estimated as the National Glycohemoglobin Standardization Program equivalent value (%) and calculated using the formula HbA 1c (%) = 1.02 9 HbA 1c (Japan Diabetes Society, %) ? 0.25 % [10] . Proteinuria was measured by spectrocolorimetry. All measurements were carried out in the clinical laboratory of Saku Central Hospital. Weight and height were measured the morning after the overnight fast. Body mass index (BMI) was calculated as weight (kg)/ height squared (m 2 ). Blood pressure was measured by trained nurses using an automatic sphygmomanometer, with participants in a seated position after at least a 5-min rest. Hypertension was defined as systolic blood pressure C140 mmHg, diastolic blood pressure C90 mmHg, or the use of antihypertensive medication. Dyslipidemia was defined as low-density lipoprotein cholesterol C3.62 mmol/ L, high-density lipoprotein cholesterol \1.03 mmol/L, triglycerides C1.69 mmol/L, or use of antihyperlipidemic medication. In addition, each examination included standard questionnaires concerning demographic characteristics, medical history, and health-related habits.
Definition of main outcomes and follow-up
Main outcomes were proteinuria C[1?] or eGFR \60 ml/ min/1.73 m 2 [11] . Participants had annual follow-ups at Saku Central Hospital, including comprehensive medical check-ups over 2 days and 1 night until either (1) the development of proteinuria, (2) deterioration in eGFR, or (3) March 2014. Individuals not examined during followup were censored on the date of their last examination. End point I was the development of deterioration in eGFR, March 2014, or the last examination. End point II was the development of proteinuria, March 2014, or the last examination.
Statistical analysis
Differences in baseline characteristics according to diabetes stage were determined using Student's t-test for normally distributed continuous data, the Mann-Whitney U test for non-normally distributed continuous data, and the chi-square test for dichotomous and categorical data. The percentages of the participants who developed hypertension and dyslipidemia during the follow-up period were calculated with measurements of blood pressure and lipid profile and the medical history information on hypertension obtained at annual health check-ups. The percentages of the participants who developed cardiovascular and cerebrovascular diseases and cancer were calculated based on the medical histories and the standard questionnaires. The chi-square test was used for these categorical data. In addition, changes in BMI were calculated by subtracting the baseline BMI from the endpoint BMI. Student's t-test was applied to the changes in BMI.
Cox proportional hazard regression analysis was used to estimate the adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) for the incidences of eGFR\60 ml/min/ 1.73 m 2 until end point I and proteinuria C[1?] until end point II in participants with borderline diabetes compared to those with normoglycemia. Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, BMI, hypertension, dyslipidemia, and smoking status. These confounders were selected from the variables that were reported as risk factors for CKD stage I or II in a previous study [12] . In addition, model 3 was adjusted for the variables adjusted for in model 2, for the change in BMI, and for newly developed hypertension, dyslipidemia, cardiovascular and cerebrovascular diseases, and cancer during the follow-up period. To consider changes in blood glucose levels during the follow-up period, we also estimated the adjusted HRs and 95 % CIs for incidences of eGFR \60 ml/min/1.73 m 2 and proteinuria among participants who did not change diabetes stage from baseline to endpoint examinations; that is, they remained normoglycemic or borderline diabetic. For additional analyses, participants with persistent borderline diabetes were divided into two groups according to baseline FPG and 2-h PG levels: borderline diabetes I (FPG 110-125 mg/dl and 2-h PG \ 200 mg/dl) and borderline diabetes II (FPG \ 110 mg/ dl and 2-h PG 140-199 mg/dl). All data were analyzed using SPSS statistical software (version 22.0 J; SPSS Japan Inc., Tokyo, Japan) and STATA statistical software (release 13; Stata Corporation, College Station, TX, USA). All reported P values are twotailed; those\0.05 were considered statistically significant. Table 1 shows baseline characteristics according to diabetes stage. With the exception of hematuria, eGFR, and proteinuria, all other variables differed significantly between the diabetes stages.
Results
Of the 2158 participants with normoglycemia at baseline, 358 developed borderline diabetes or diabetes. Of the 691 participants with borderline diabetes at baseline, 185 participants developed diabetes. Table 2 shows the characteristics of changes in cardiometabolic risk factors and the development of cardiovascular and cerebrovascular diseases and cancer during the follow-up period. Based on measurements of eGFR \60 ml/min/1.73 m 2 and proteinuria C[?1] performed during the follow-up period, participants with different stages of diabetes differed significantly in the average BMI change and the percentage of participants who developed hypertension. Table 3 shows multivariable adjusted HRs and 95 % CIs for the incidence of eGFR \60 ml/min/1.73 m 2 and proteinuria among participants with borderline diabetes. Among all participants, the median follow-up was 4.9 years for eGFR \60 ml/min/1.73 m 2 and 4.9 years for proteinuria (total person-years: 12,103 for eGFR \60 ml/ min/1.73 m 2 and 11,422 for proteinuria). During this period, 335 individuals developed eGFR \60 ml/min/1.73 m 2 and 136 individuals developed proteinuria. The risk for eGFR \60 ml/min/1.73 m 2 was not significantly greater for participants with borderline diabetes compared with those with normoglycemia in models 2 and 3. The risk of proteinuria was significantly increased for participants with borderline diabetes in model 1, although this risk was attenuated after multivariable adjustment.
Of the 2849 participants, about 1900 participants did not change diabetes stage from baseline to endpoint examination. The median follow-up was 4.9 years for eGFR \60 ml/min/1.73 m 2 and 4.9 years for proteinuria (total person-years: 7844 for eGFR \60 ml/min/1.73 m 2 and 8292 for proteinuria). During this period, 224 individuals developed eGFR \60 ml/min/1.73 m 2 and 100 individuals developed proteinuria. Similarly, the risk of eGFR\60 ml/ min/1.73 m 2 was not significantly increased for participants with persistent borderline diabetes (borderline diabetes ? borderline diabetes). On the other hand, the risk of proteinuria was significantly increased for participants 
Discussion
This is the first report of a prospective cohort study that investigated the association between borderline diabetes defined by 75-g OGTT and the incidence of eGFR\60 ml/ min/1.73 m 2 and proteinuria by considering changes in diabetes stage during the follow-up period. The present study demonstrated that individuals with borderline diabetes had a high risk of proteinuria. Furthermore, individuals with persistent borderline diabetes had a significantly higher risk of proteinuria compared with individuals with persistent normoglycemia. On the other hand, the risk of eGFR \60 ml/min/1.73 m 2 did not increase, even among individuals with persistent borderline diabetes.
Many studies have reported that individuals with borderline diabetes were at high risk for developing diabetes, with between 10 and 60 % of those individuals developing diabetes [13] [14] [15] . On the other hand, individuals with borderline diabetes are prone to reverting to normoglycemia [15, 16] . Therefore, it may not be possible to clearly identify the risk of diabetes complications among patients with borderline diabetes based only on baseline blood glucose levels in a prospective follow-up study. Yamagata et al. reported the association between impaired glucose tolerance defined by fasting plasma glucose or casual plasma glucose levels and CKD, and demonstrated that participants with impaired glucose tolerance had a significant and high risk of proteinuria: the HRs were 1.21 in men and 1.19 in women [12] . However, participants with impaired glucose tolerance in the previous study included individuals who changed diabetes stage during the followup period. In the present study, we assessed the risk of eGFR \60 ml/min/1.73 m 2 and proteinuria among individuals with persistent borderline diabetes. As a result, individuals with persistent borderline diabetes had a significantly higher risk of proteinuria compared with individuals with persistent normoglycemia. Consequently, we suggest that borderline diabetes per se is a risk factor for proteinuria.
It has been reported that hyperfiltration, which is a symptom of diabetic nephropathy, occurs in patients with early type 2 diabetes [17] . Hyperfiltration is characterized by albuminuria and increased GFR. After multivariable adjustment was performed in our study, persistent borderline diabetes was found to increase the risk of proteinuria and slightly decrease the risk of a low eGFR. Proteinuria in patients with borderline diabetes may be associated with hyperfiltration. One of the mechanisms for hyperfiltration is glomerular hypertension caused by the vasodilatory effect of nitric oxide on afferent glomerular arterioles and the vasoconstrictive effect of angiotensin II on efferent glomerular arterioles associated with hyperglycemia [18, 19] . In addition, hyperinsulinemia causes hyperfiltration, endothelial dysfunction, and increased vascular permeability [20] . Because borderline diabetes may cause hyperfiltration, it may be important to consider whether it is present at this stage in order to achieve early prevention of CKD. Many studies have reported that individuals with a high level of 2-h PG have higher risks for cardiovascular and all-cause mortality than individuals with a high level of FPG [21] [22] [23] [24] . In addition, a high level of 2-h PG but not a high level of FPG has been reported to be associated with a high risk of retinopathy [5] . In the present study, the incidence of proteinuria among participants with borderline diabetes and a high level of 2-h PG did not differ significantly from the incidence of proteinuria among participants with borderline diabetes and a high level of FPG. Because a high level of 2-h PG can be diagnosed by an OGTT, but not by a fasting or casual blood test, the presence of a high level of 2-h PG may be missed when only a fasting or casual blood test is performed. In terms of preventing complications of diabetes, it may be just as important to identify a high level of 2-h PG as it is to identify a high level of FPG, as either can increase the risk of such complications.
Our study has several limitations. First, proteinuria was diagnosed by a single urine test. Because proteinuria fluctuates according to various conditions, our study may have included not only those with persistent proteinuria but also those with transient proteinuria. To exclude the influence of another cause of proteinuria, such as an infectious disease, we adjusted for hsCRP at the end points. The results did not change when we did this (data not shown). However, other influences were not completely controlled. Second, there was the possibility of selection bias, as participants were individuals who underwent routine comprehensive medical check-ups. A nationwide screening program of the Specific Health Check-up and Guidance System in 2008 reported that the percentage of participants with eGFR \60 ml/min/1.73 m 2 was 14.5 % and the percentage of participants with proteinuria C[1?] was 5.4 % in Japanese aged 40-74 years [25] . In the present study, the percentage of participants with eGFR \60 ml/min/1.73 m 2 was 15.5 % and the percentage of participants with proteinuria C1? was 5.2 % in participants aged 40-74 years at baseline (N = 4421). These percentages are almost the same, which may minimize any possible selection bias in this study. Finally, information regarding concomitant agents that may affect the prognosis of CKD (such as angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or statins) was not available in this study. Therefore, the effects of metabolic diseases such as hypertension and dyslipidemia on CKD were not completely controlled.
In conclusion, individuals with persistent borderline diabetes had a significantly higher risk for proteinuria compared with individuals with persistent NG, even if they did not develop diabetes. Early intervention is important to prevent kidney disease associated with diabetes.
